retatrutide phase 2 obesity trial Survodutide vs. for Weight Loss Retatrutide Safety, Side Effects &

In the Carmina study, 33% of participants experienced morning nausea, and about 7% dealt with occasional vomiting

IDF Diabetes Atlas, 8th edn., 2017

There is no formally established link between specific foods and serious adverse outcomes with retatrutide at this stage, but caution is prudent given the drug's mechanism of action

Here is a direct comparison from published Phase 2 and Phase 3 data: Semaglutide (Ozempic/Wegovy): Average weight loss of 14.9% at 68 weeks in the STEP 1 trial Tirzepatide (Mounjaro): Average weight loss of 20.9% at 72 weeks in the SURMOUNT-1 trial Retatrutide: Average weight loss of 24.2% at 48 weeks in the Phase 2 trial Retatrutide reached a higher percentage of weight loss in fewer weeks

Retardo del vaciamiento gstrico: el estmago se vaca ms lentamente, lo que prolonga la sensacin de saciedad